Jeck, Julia http://orcid.org/0000-0002-4669-690X
Jakobs, Florian
Kron, Anna http://orcid.org/0000-0002-3047-6486
Franz, Jennifer
Cornely, Oliver A.
Kron, Florian http://orcid.org/0000-0003-4907-7490
Funding for this research was provided by:
gilead sciences
Universitätsklinikum Köln
Article History
Received: 11 June 2021
Accepted: 11 August 2021
First Online: 18 August 2021
Declarations
:
: A. Kron received consultancy honoraria from Takeda, BMS, AbbVie, Novartis, and MSD. O. A. Cornely has received research grants from, is an advisor to, or received lecture honoraria from Actelion, Allecra Therapeutics, Al-Jazeera Pharmaceuticals, Amplyx, Astellas, Basilea, Biosys, Cidara, Da Volterra, Entasis, F2G, Gilead, Grupo Biotoscana, Immunic, IQVIA, Janssen, Matinas, Medicines Company, MedPace, Melinta Therapeutics, Menarini, Merck/MSD, Mylan, Nabriva, Noxxon, Octapharma, Paratek, Pfizer, PSI, Roche Diagnostics, Scynexis, and Shionogi. F. Kron received lecture honoraria and/or advisory board and consultancy honoraria from Pfizer Inc, MSD, Bristol Myers Squibb, Novartis, Takeda, Shire, Amgen, Janssen-Cillag, Celgene, Gilead, Bayer, Mundipharma, Riemser, Medac, Jazz Pharmaceuticals, Medipolis, Aposan, Hogan Lovells, Simon Kucher, Orphoz-McKinsey, and Aktiva Gesundheitsberatung. All other authors: None to declare. J. Jeck, F. Jakobs, and A. Kron are employees of VITIS Healthcare Group, who were paid consultants to GILEAD Sciences, Inc. in connection with the development of this manuscript.
: An ethical appraisal was not necessary or prescribed.
: Not applicable.
: The authors confirm that this work has not been published before; that is not under consideration for publication elsewhere; that the submitted version has been approved by all co-authors.